Somaxon Pharmaceuticals Inc. got approval for its insomnia drug Silenor after three tries from the FDA. The company had initially sent their drug application as early as January, 2008 which eventually got declined. Somaxon resubmitted its application on January 21, 2010, which was considered as Class 1 resubmission with a two-month review cycle resulting in a decision date by March 21, 2010.
Silenor has not been designated as a controlled substance by the U.S. Drug Enforcement Administratio
